Catalyst Pharmaceuticals, Inc.
HealthcareNASDAQ:CPRX · NASDAQ Capital Market
-$0.01 today
Vol 0.78M · Avg 2.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$597.0M of revenue converted into $221.3M of net income for the selected period. Gross margin is 82.3% and net margin is 37.1%, showing how much revenue survives after costs and taxes. EPS is $1.73, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $589.0M +19.8% | $491.7M +23.5% | $398.2M +85.9% | $214.2M +52.1% | $140.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $87.3M +26.7% | $68.8M +32.5% | $52.0M +51.1% | $34.4M +57.2% | $21.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $501.7M +18.6% | $422.9M +22.1% | $346.2M +92.6% | $179.8M +51.2% | $118.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 85.2% -0.8pp | 86.0% -1.0pp | 86.9% +3.0pp | 83.9% -0.5pp | 84.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $12.7M +0.5% | $12.6M -86.4% | $93.2M +370.7% | $19.8M +16.8% | $16.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $193.8M +9.0% | $177.7M +32.9% | $133.7M +134.2% | $57.1M +15.0% | $49.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $244.0M +7.1% | $227.8M -12.2% | $259.4M +232.7% | $78.0M +17.1% | $66.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $37.9M +0.3% | $37.8M +14.9% | $32.9M +2553.8% | $1.2M +545.3% | $192.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $321.4M +26.5% | $254.0M +99.4% | $127.4M +20.2% | $106.0M +100.5% | $52.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 54.6% +2.9pp | 51.7% +19.7pp | 32.0% -17.5pp | 49.5% +11.9pp | 37.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $257.8M +32.1% | $195.1M +124.8% | $86.8M -14.8% | $101.8M +94.4% | $52.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 43.8% +4.1pp | 39.7% +17.9pp | 21.8% -25.7pp | 47.5% +10.3pp | 37.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $16.1M | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $25.7M +21.8% | $21.1M +174.6% | $7.7M +167.2% | $2.9M +921.6% | $282.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $283.5M +31.1% | $216.3M +128.8% | $94.5M -9.7% | $104.7M +98.8% | $52.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 48.1% +4.2pp | 44.0% +20.2pp | 23.7% -25.2pp | 48.9% +11.5pp | 37.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $69.2M +32.1% | $52.4M +126.7% | $23.1M +6.8% | $21.6M +64.1% | $13.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $214.3M +30.8% | $163.9M +129.5% | $71.4M -14.0% | $83.1M +110.4% | $39.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 36.4% +3.1pp | 33.3% +15.4pp | 17.9% -20.9pp | 38.8% +10.8pp | 28.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +26.8% | $1 +106.0% | $1 -16.3% | $1 +110.5% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +28.2% | $1 +107.9% | $1 -16.0% | $1 +102.7% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $122.3M +3.2% | $118.5M +11.5% | $106.3M +2.8% | $103.4M -0.0% | $103.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $127.3M +1.9% | $124.9M +9.8% | $113.8M +2.1% | $111.4M +3.3% | $107.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CPRX generate?
Catalyst Pharmaceuticals, Inc. (CPRX) reported $588.99M of revenue in fiscal 2025.
Is CPRX profitable?
Catalyst Pharmaceuticals, Inc. (CPRX) reported $214.33M of net income, with a net margin of 36.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.